MDGL heads into its June 17 earnings date with short sellers in modest retreat and a cost-to-borrow that just doubled in a single session, creating a quietly charged setup for a stock that has barely moved in a month.
The most notable shift in short positioning is the direction of travel. Short interest as a percentage of free float has fallen from a local peak around 31.6% in early May to roughly 29.9% now — a meaningful pullback of nearly two percentage points over three weeks. The catalyst appears to have been the May 6 earnings print, which sent the stock up 6.4% on the day, prompting a wave of short covering. Since then, shorts have stabilised rather than rebuilt, holding in a tight 29.7%–30.1% band. At 16-plus days to cover on official FINRA data, any accelerated covering would take time to clear. The contrast with the pre-earnings setup is the key story: shorts are lighter now than they were when the last result landed.
The borrow market tells a more ambiguous story. Cost to borrow spiked on May 26 to 0.71% — nearly double the prior day's 0.39% and the highest reading in the trailing 30-day window. That's still a low absolute cost; this is not an expensive borrow by any measure. But the move is sharp enough to watch. Availability remains very loose at around 619% of estimated short interest, well above the 52-week low of 393%. There is no sign of a supply squeeze in the lending pool. The CTB jump looks more like noise or a short-term demand pulse than the start of a structural tightening.
Options traders are currently the least defensive they've been this year. The put/call ratio is running at 0.31, essentially flat with its 20-day average of 0.31 and not far above the 52-week low of 0.235. For comparison, it was 0.38 in the days immediately after the last earnings. The read is straightforward: call positioning dominates, and sentiment in the options market is notably bullish relative to the past 12 months. That contrasts with the elevated short book and sets up an interesting divergence heading into the June 17 print.
Analyst coverage skews strongly positive. Truist raised its target to $709 on May 13, two weeks after the earnings beat. The majority of the covering firms carry Buy or Outperform ratings, and the consensus mean target of $679 implies roughly 30% upside to the current price near $524. The bull case centres on Rezdiffra's MASH franchise, extended patent protection, and the pipeline of combination therapies. Bears flag clinical execution risk, competitive pressure, and the possibility that Rezdiffra's real-world efficacy falls short of label-data expectations. Bank of America, the one notable holdout at Neutral with a $529 target, is essentially saying the stock is close to fairly valued at current levels — a view that has looked increasingly out of step with the broader consensus, though that target was set in February and may not fully reflect recent commercial progress.
On the institutional side, Janus Henderson added 433,000 shares as of May 1 — the most material new buying visible in the recent holder data. Paulson & Co. trimmed 315,000 shares in Q1, a meaningful reduction. Baker Bros., the largest disclosed holder at 9.3%, made no change. Insider activity this week consisted of Director Richard Levy selling approximately 4,900 shares across multiple tranches on May 22 for aggregate proceeds near $1.7 million — a routine-sized disposition for a director at these price levels, rated low significance.
The last two earnings reactions provide useful anchoring. The May 6 release produced a 6.4% one-day gain. The April 28 release moved the stock down 0.3% on the day and 3.4% over five days. Two events are too few to call a pattern, but the asymmetry is visible: the bigger reaction was positive, and it came after the short book was heavier. With shorts lighter into June 17 and options traders positioned for more upside than downside, the question for next month's print shifts to whether commercial execution on Rezdiffra can clear what is now a higher bar.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
